Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hope for treating relapse to methamphetamine abuse

14.11.2008
Vigabatrin shown to block reinstatement of drug-seeking behavior

A new study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory suggests that vigabatrin (a.k.a. gamma vinyl-GABA, or GVG) blocks drug-seeking behavior in animals previously trained to associate methamphetamine with a particular environment.

Specifically, animals pre-treated with vigabatrin lost interest in spending time in a location where they had previously been given methamphetamine. The results will appear in the February 2009 issue of Synapse, now available online.

"Reinstatement of drug-seeking behavior after an extended period of abstinence is the number-one cause of drug-addiction relapse," said Brookhaven neuroanatomist Stephen Dewey, who led the research team. "This animal study suggests that vigabatrin could potentially prevent human methamphetamine addicts from relapsing."

According to the National Institute on Drug Abuse, methamphetamine is a very addictive stimulant that is quickly becoming an American public health epidemic. There is currently no effective treatment for methamphetamine addiction.

Vigabatrin is a pharmaceutical agent first tested as a possible treatment for a variety of addictions in animal studies led by Dewey at Brookhaven Lab (http://www.bnl.gov/CTN/GVG/). It is the only drug that has been shown to block any behavior associated with methamphetamine use, and is currently being tested by Catalyst Pharmaceutical Partners (http://www.catalystpharma.com/) for safety and efficacy against cocaine and methamphetamine addiction in humans in Phase II clinical trials across the U.S.

"In human drug abusers, many things can cause relapse — exposure or access to drugs, environmental cues that trigger thoughts of the drug, or stress," said Dewey. "If vigabatrin can prevent relapse, it could have a huge impact by helping drug abusers regain control over their lives."

In the current study, rats were first put through a series of conditioning tests that taught them to expect methamphetamine in one chamber of a three-chamber apparatus and saline solution in another chamber. The researchers then allowed the rats to roam freely among the three chambers. If the rats spent the majority of their time in the chamber where they had been given methamphetamine, the scientists knew they had established a "conditioned place preference."

Once this preference was established, the researchers extinguished it by giving the rats saline injections in both chambers, again allowing the animals to have free access to all chambers until the rats had no preference for the previously methamphetamine-associated chamber for at least six consecutive days.

Once extinguished, however, it is possible for a conditioned preference to be reinstated — just as it is possible for a recovered drug addict to relapse. To reinstate the place preference in this experiment, Brookhaven scientists injected the rats with methamphetamine in the neutral chamber. Immediately, rats went to the chamber where they had received methamphetamine and remained there for the duration of the exposure period.

Then, once the reinstatement of a preference was clearly demonstrated, the researchers tested the effectiveness of vigabatrin at blocking it. They pre-treated animals with vigabatrin two-and-a-half hours before giving them another priming dose of methamphetamine followed by free access to all three chambers. When pre-treated with vigabatrin, the rats no longer showed any preference for one chamber over another.

Dewey's group is now conducting studies to examine whether GVG will also block an environmental cue previously shown to produce relapse to drug-seeking behavior.

"These studies have wide implications for addressing the number-one cause of relapse to drug seeking behavior. If we can successfully block drug-induced reinstatement, then our ability to block environmental cue-induced relapse is significantly enhanced," Dewey said.

Karen McNulty Walsh | EurekAlert!
Further information:
http://www.bnl.gov

Further reports about: Drug Methamphetamine Stress Vigabatrin methamphetamine abuse

More articles from Studies and Analyses:

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>